Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin

被引：0

作者：

Sulkowski, Mark S. ^{[1
]}

Fried, Michael W. ^{[11
]}

Ozaras, Resat ^{[3
]}

Isakov, Vasily ^{[4
]}

Wyles, David L. ^{[5
]}

Ferenci, Peter ^{[6
]}

Feld, Jordan J. ^{[7
]}

Calinas, Filipe ^{[8
]}

Gschwantler, Michael ^{[9
]}

King, Martin ^{[10
]}

Baykal, Tolga ^{[10
]}

Gane, Edward J. ^{[2
]}

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

[2] Auckland City Hosp, Liver Unit, Auckland, New Zealand

[3] Istanbul Univ, Istanbul, Turkey

[4] Russian Acad Med Sci, Inst Nutr, Moscow 109801, Russia

[5] Univ Calif San Diego, La Jolla, CA 92093 USA

[6] Univ Klin Fuer Innere Med III, Vienna, Austria

[7] Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada

[8] EPE Hosp St Antonio Capuchos, Ctr Hosp Lisboa Cent, Lisbon, Portugal

[9] Wilhelminenspital Stadt Wien, Vienna, Austria

[10] AbbVie, N Chicago, IL USA

[11] Univ N Carolina, Liver Program, Chapel Hill, NC USA

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1950

引用

页码：1144A / 1145A

页数：2

共 50 条

[1] Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin
Alqahtani, S.
Ozaras, R.
Isakov, V.
Wyles, D.
Ferenci, P.
Feld, J. J.
Calinas, F.
Gschwantler, M.
Gane, E.
Crawford, D.
Jacobson, I. M.
Dumas, E. O.
King, M.
Sulkowski, M.
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (04) : 280 - 286
[2] SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
Colombo, Massimo
Weiland, Ola
Cohen, Daniel E.
DuFour, Jean-Francois J.
Reynaert, Hendrik
Diago, Moises
Villa, Erica
Streinu-Cercel, Adrian
Xie, Wangang
Baykal, Tolga
Enejosa, Jeffrey
Coakley, Eoin
Trinh, Roger
Podsadecki, Thomas
HEPATOLOGY, 2014, 60 : 1131A - 1131A
[3] SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
Jacobson, Ira M.
DuFour, Jean-Francois J.
Enejosa, Jeffrey
de Knegt, Robert J.
Ferenci, Peter
Reynaert, Hendrik
Di Bisceglie, Adrian M.
Larsen, Lois
Baykal, Tolga
Rodrigues-, Lino, Jr.
Podsadecki, Thomas
Jensen, Donald M.
Poordad, Fred
HEPATOLOGY, 2014, 60 : 1133A - 1133A
[4] TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Coinfected Patients Treated with ABT-450/r/Ombitasvir, Dasabuvir and Ribavirin
Wyles, David L.
Sulkowski, Mark S.
Eron, Joseph J.
Trinh, Roger
Lalezari, Jay
Slim, Jihad
Gathe, Joseph C.
Wang, Chia C.
Elion, Richard
Bredeek, Fritz
Brennan, Robert O.
Blick, Gary
Khatri, Amit
Gibbons, Krystal
Hu, Yiran
Fredrick, Linda
Pilot-Matias, Tami
Da Silva-Tillmann, Barbara
McGovern, Barbara H.
Campbell, Andrew L.
Podsadecki, Thomas
HEPATOLOGY, 2014, 60 : 1136A - 1137A
[5] ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, Peter
Bernstein, David
Lalezari, Jacob
Cohen, Daniel
Luo, Yan
Cooper, Curtis
Tam, Edward
Marinho, Rui T.
Tsai, Naoky
Nyberg, Anders
Box, Terry D.
Younes, Ziad
Enayati, Pedram
Green, Sinikka
Baruch, Yaacov
Bhandari, Bal Raj
Caruntu, Florin Alexandru
Sepe, Thomas
Chulanov, Vladimir
Janczewska, Ewa
Rizzardini, Giuliano
Gervain, Judit
Planas, Ramon
Moreno, Christophe
Hassanein, Tarek
Xie, Wangang
King, Martin
Podsadecki, Thomas
Reddy, K. Rajender
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (21): : 1983 - 1992
[6] SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
Maieron, Andreas
Puoti, Massimo
Enejosa, Jeffrey
Ben-Ari, Ziv
Norkrans, Gunnar
Romero-Gomez, Manuel
Xie, Wangang
Cohen, Daniel
Podsadecki, Thomas
Andreone, Pietro
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S131 - S131
[7] SVR12 of 99% achieved with a ribavirin-free regimen ABT-450/R/ombitasvir and dasabuvir in HCV genotype 1b-infected patients
Maieron, A.
Puoti, M.
Enejosa, J. V.
Andreone, P.
Ari, Z. B.
Norkrans, G.
Romero-Gomez, M.
Xie, W.
Cohen, D. E.
Podsadecki, T.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 156 - 156
[8] Management of Hemoglobin Decrease in Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients
Rustgi, Vinod
Bernstein, David
Sepe, Thomas
King, William
Diago, Moises
Andreone, Pietro
Forton, Daniel
Reesink, Hendrik
Ferenci, Peter
Hu, Yiran
Enejosa, Jeffrey
Cohen, Daniel
Luo, Yan
Pedrosa, Marcos
Vierling, John
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S133
[9] Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients
Bernstein, David
Tsai, Naoky
Hassanein, Tarek
Rodriguez-Perez, Federico
Romero-Gomez, Manuel
Marinho, Rui
Planas Vila, Ramon
Colombo, Massimo
Lovell, Sandra
Enejosa, Jeffrey
Luo, Yan
Cohen, Daniel
Pedrosa, Marcos
Reddy, K. Rajender
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S134
[10] TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients with Cirrhosis, Regardless of Baseline Characteristics
Fried, Michael W.
Forns, Xavier
Reau, Nancy
Wedemeyer, Heiner
Shiffman, Mitchell L.
Castro, Angeles
Mutimer, David J.
Lee, Samuel S.
Trinh, Roger
Lovell, Sandra S.
Canizaro, Leticia
Pedrosa, Marcos
Berg, Thomas
HEPATOLOGY, 2014, 60 : 238A - 238A

← 1 2 3 4 5 →